Janice Chen, CTO and Co-founder of Our Portfolio Company Mammoth Biosciences, is Spotlighted in CNBC.
In this edition:
- Precision Immunology Company Endpoint Health Partners with Grifols on Critical Immune System Illness
- Mammoth Biosciences Receives FDA Emergency Use Authorization for Covid-19 Test, Partners with Bayer to Target Genetic Diseases of the Liver
- Qventus Announces $50M Growth Financing Enabling Market Presence Expansion
- Study Published in Nature Proves Mirvie’s RNA Platform Predicts Pregnancy Complications Months Before Symptoms Appear
- Mammoth Biosciences Expands Leadership Team with the Appointment of Elaine Sun as COO/CFO
- Arvind Shares his POV on Climate Change, Investment Values and Guiding Principles, Plus Pitch Advice for Founders
Precision Immunology Company Endpoint Health Partners with Grifols on Critical Immune System Illness
Precision immunology platform company Endpoint Health has partnered with Grifols to develop and commercialize an Antithrombin III (AT-III) therapy to treat sepsis. This collaboration marks a huge step towards getting new treatments to market for critical immune system dysfunctions like sepsis that kill more people than all cancers combined.
Mammoth Biosciences Receives FDA Emergency Use Authorization for Covid-19 Test, Partners with Bayer to Target Genetic Diseases of the Liver
Mammoth Biosciences’ ground-breaking CRISPR-based molecular diagnostic system for Covid-19 testing received Emergency Use Authorization from the FDA. Mammoth continues to redefine engineering biology through their new strategic collaboration with Bayer to develop in-vivo gene therapies, starting with diseases of the liver, using Mammoth’s cutting edge CRISPR platform.
Qventus Announces $50M Growth Financing Enabling Market Presence Expansion
Each year the health care system loses approximately $1 trillion to waste, and one major contributor is inefficient operations. Qventus’s AI-enabled care operations automation software tackles this problem head on with proven results. In 2021 alone, Qventus automated access and patient flow for more than 2 million patient encounters, eliminating over 200 years of excess hospital stay days and resulting in a 10X return on investment.
Study Published in Nature Proves Mirvie’s RNA Platform Predicts Pregnancy Complications Months Before Symptoms Appear
Unexpected complications affect one in five pregnancies, and yet today women and doctors lack a reliable way to detect complications before symptoms appear. Mirvie’s proprietary RNA platform is the first of its kind to predict unexpected complications by revealing the underlying biology of each pregnancy. This technology is set to revolutionize pregnancy health by allowing women and their doctors to intervene before underlying issues become health crises.
Mammoth Biosciences Expands Leadership Team with the Appointment of Elaine Sun as COO/CFO
Mammoth Biosciences has appointed Elaine Sun as its new Chief Operating Officer/Chief Financial Officer, marking a notable expansion of its leadership team. Elaine has over 25 years of experience in the life sciences industry and joins from Halozyme, a biotechnology company that develops novel oncology therapies.
Arvind Shares his POV on Climate Change, Investment Values and Guiding Principles, Plus Pitch Advice for Founders
Arvind shares his stance on morality in investment and shares how his personal experiences keep him grounded on his mission to improve and save lives through investing in planetary health. Arvind also recently shared some candid pitch advice for first time founders and where he’s looking for the next iconic companies.